13.06
price up icon2.67%   0.34
 
loading
Schlusskurs vom Vortag:
$12.72
Offen:
$12.65
24-Stunden-Volumen:
701.93K
Relative Volume:
1.21
Marktkapitalisierung:
$661.14M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-2.4829
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+1.40%
1M Leistung:
+18.51%
6M Leistung:
+33.13%
1J Leistung:
+33.81%
1-Tages-Spanne:
Value
$12.61
$13.42
1-Wochen-Bereich:
Value
$12.61
$13.99
52-Wochen-Spanne:
Value
$5.035
$13.99

Regenxbio Inc Stock (RGNX) Company Profile

Name
Firmenname
Regenxbio Inc
Name
Telefon
240-552-8181
Name
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
353
Name
Twitter
@REGENXBIO
Name
Nächster Verdiensttermin
2025-08-01
Name
Neueste SEC-Einreichungen
Name
RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGNX
Regenxbio Inc
13.06 643.93M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.64 110.88B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
726.21 72.79B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
890.11 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
404.46 54.85B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
189.85 41.41B 447.02M -1.18B -906.14M -6.1812

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Herabstufung Goldman Buy → Neutral
2025-02-07 Fortgesetzt Raymond James Outperform
2024-11-15 Fortgesetzt Morgan Stanley Overweight
2024-10-10 Fortgesetzt Raymond James Outperform
2024-06-07 Eingeleitet Goldman Buy
2024-03-11 Eingeleitet H.C. Wainwright Buy
2024-03-08 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-21 Fortgesetzt Raymond James Outperform
2023-11-01 Eingeleitet Stifel Buy
2023-06-02 Eingeleitet Robert W. Baird Outperform
2022-06-23 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Wedbush Neutral
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-01-06 Hochstufung Raymond James Outperform → Strong Buy
2020-12-16 Eingeleitet UBS Buy
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2019-08-20 Hochstufung SVB Leerink Underperform → Mkt Perform
2019-06-18 Bestätigt Chardan Capital Markets Buy
2019-06-14 Fortgesetzt Raymond James Outperform
2019-06-05 Bestätigt Chardan Capital Markets Buy
2019-02-25 Hochstufung Evercore ISI In-line → Outperform
2019-02-05 Hochstufung Raymond James Outperform → Strong Buy
2018-12-17 Bestätigt Chardan Capital Markets Buy
2018-11-08 Bestätigt BofA/Merrill Neutral
2018-08-08 Bestätigt Chardan Capital Markets Buy
2018-07-23 Herabstufung BofA/Merrill Buy → Neutral
2018-07-10 Bestätigt Chardan Capital Markets Buy
2018-05-09 Bestätigt Barclays Overweight
2018-04-09 Bestätigt Chardan Capital Markets Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-02-13 Eingeleitet Mizuho Neutral
2017-11-09 Fortgesetzt Morgan Stanley Overweight
Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
Dec 08, 2025

REGENXBIO (NASDAQ:RGNX) Reaches New 52-Week HighShould You Buy? - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Wet Age-Related Macular Degeneration Market Growth - openPR.com

Dec 08, 2025
pulisher
Dec 08, 2025

Voss Capital LP Boosts Stock Holdings in REGENXBIO Inc. $RGNX - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

REGENXBIO Inc. $RGNX is 22NW LP's 5th Largest Position - MarketBeat

Dec 08, 2025
pulisher
Dec 05, 2025

Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

What insider trading reveals about REGENXBIO Inc. stockJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Why global investors buy REGENXBIO Inc. (RB0) stock2025 Market WrapUp & Safe Capital Allocation Plans - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulus2025 Big Picture & Safe Entry Zone Identification - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Can REGENXBIO Inc. stock resist market sell offsQuarterly Profit Review & Technical Pattern Based Signals - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Is REGENXBIO Inc. stock resilient to inflationGold Moves & Fast Exit Strategy with Risk Control - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX - MarketBeat

Dec 03, 2025
pulisher
Dec 02, 2025

Will REGENXBIO Inc. (RB0) stock see valuation expansionWeekly Trade Analysis & Reliable Trade Execution Plans - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

Dec 01, 2025
pulisher
Dec 01, 2025

Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights

Dec 01, 2025
pulisher
Nov 30, 2025

How (RGNX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

Nov 30, 2025
pulisher
Nov 30, 2025

26,773 Shares in REGENXBIO Inc. $RGNX Bought by Rockefeller Capital Management L.P. - MarketBeat

Nov 30, 2025
pulisher
Nov 28, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Nov 28, 2025
pulisher
Nov 27, 2025

Gainers Report: Is REGENXBIO Inc. stock a contrarian buyJuly 2025 Summary & Risk Managed Trade Strategies - BỘ NỘI VỤ

Nov 27, 2025
pulisher
Nov 27, 2025

REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript - The Globe and Mail

Nov 27, 2025
pulisher
Nov 27, 2025

Regenxbio files $300M mixed securities shelf - MSN

Nov 27, 2025
pulisher
Nov 27, 2025

Transcript : REGENXBIO Inc. Presents at Stifel 2025 Healthcare Conference, Nov-11-2025 01 - marketscreener.com

Nov 27, 2025
pulisher
Nov 26, 2025

Regenxbio files $300M mixed shelf offering - MSN

Nov 26, 2025
pulisher
Nov 26, 2025

Regenxbio (RGNX) Files for $300M Securities Offering - GuruFocus

Nov 26, 2025
pulisher
Nov 26, 2025

Regenxbio files for mixed shelf of up to $300 millionSEC filing - marketscreener.com

Nov 26, 2025
pulisher
Nov 26, 2025

[S-3] REGENXBIO Inc. Shelf Registration Statement | RGNX SEC FilingForm S-3 - Stock Titan

Nov 26, 2025
pulisher
Nov 25, 2025

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet? - 富途牛牛

Nov 25, 2025
pulisher
Nov 25, 2025

REGENXBIO to Participate in Upcoming Investor Conference - PR Newswire

Nov 25, 2025
pulisher
Nov 25, 2025

Regenxbio up 4% following additional data on Duchenne gene therapy asset - MSN

Nov 25, 2025
pulisher
Nov 24, 2025

Brokers Set Expectations for REGENXBIO FY2026 Earnings - MarketBeat

Nov 24, 2025
pulisher
Nov 21, 2025

REGENXBIO (NASDAQ:RGNX) Given Buy Rating at Chardan Capital - MarketBeat

Nov 21, 2025
pulisher
Nov 20, 2025

RGNX S-8及美國證券交易委員會申報文件 - Yahoo 財經

Nov 20, 2025
pulisher
Nov 20, 2025

Chardan Capital Maintains Buy Rating for RGNX with $52 Price Tar - GuruFocus

Nov 20, 2025
pulisher
Nov 20, 2025

Is REGENXBIO Inc. (RB0) stock safe for risk averse investors2025 Earnings Impact & Precise Swing Trade Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Will REGENXBIO Inc. (RB0) stock profit from AI boomJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

How REGENXBIO Inc. stock responds to policy changes2025 Investor Takeaways & Long-Term Growth Portfolio Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Visualizing REGENXBIO Inc. stock with heatmapsWeekly Trade Recap & Intraday High Probability Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Reversal indicators forming on REGENXBIO Inc. stock2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Trading Systems Reacting to (RGNX) Volatility - news.stocktradersdaily.com

Nov 19, 2025
pulisher
Nov 19, 2025

Will REGENXBIO Inc. stock split again soonTrade Ideas & Precise Buy Zone Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What data driven models say about REGENXBIO Inc.’s futurePortfolio Value Summary & Consistent Income Trade Recommendations - newser.com

Nov 19, 2025

Finanzdaten der Regenxbio Inc-Aktie (RGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):